WARNER-LAMBERT ACCUPRIL SALES UP 37% TO $312 MIL., LEADING Rx SALES GROWTH IN 1995; CARDINAL REPORTS SUBSTANTIALLY IMPROVED GROSS MARGINS
Executive Summary
Warner-Lambert's 1995 pharmaceutical sales were fueled by growth from the ACE inhibitor Accupril, which posted a sales gain of 37% and full-year revenues of $312 mil. Warner-Lambert reported Jan. 23 that overall 1995 sales worldwide increased 10% to $7.04 bil. Sales for the year included a 7% unit volume gain, the company noted. Earnings for the year increased 7% to $740 mil. and included a third quarter, pre-tax charge of $117 mil. from the sale of the PRO toothbrush business.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth